Group 1 - Johnson & Johnson was ordered to pay $966 million (approximately 6.88 billion RMB) in a lawsuit related to its talc-based baby powder, marking the highest compensation awarded to a single plaintiff in 15 years of litigation [1] - The lawsuit was initiated by the family of May Moore, who died from mesothelioma, alleging that the baby powder contained asbestos fibers, which are linked to the rare cancer [1] - Johnson & Johnson has acknowledged that it was aware of the potential presence of asbestos in its talc products since the 1970s but did not disclose this risk to the public [1] Group 2 - Merck's Rofecoxib (Vioxx) was withdrawn from the market in 2004 due to increased cardiovascular risks, leading to a settlement of $48.5 billion for thousands of lawsuits related to heart disease and other conditions [2] - The FDA had approved Rofecoxib in 1999, but long-term studies indicated potential links to colorectal cancer, prompting Merck to take action [2] Group 3 - Sanofi's Zantac (Ranitidine) faced lawsuits after a laboratory found potential carcinogen NDMA in the drug, leading to a significant drop in stock value and potential losses of $45 billion for the companies involved [3] - By 2024, Sanofi agreed to settle approximately 4,000 personal injury claims related to Zantac, while over 75,000 cases remained pending in Delaware [3] Group 4 - Eisai's Belviq was withdrawn from the market in 2020 after studies indicated a slightly higher cancer occurrence rate among users, affecting around 8 million patients [5] - The FDA issued a safety warning advising patients to discontinue use and consult their doctors following the withdrawal of Belviq [5]